Shareholders in Medlab Clinical have been informed that the company's operations are expected to come to an end next month.
In a short statement released to the ASX this afternoon, chief executive Sean Hall said shareholders would receive details of unspecified "transactions" alongside a formal notice convening an extraordinary general meeting.
The EGM is scheduled for September, or the "soonest possible date," according to Hall.
"It is anticipated that the outcome from this meeting will conclude the operations of the company," Hall said in the update. "We thank shareholders for their patience and will update accordingly."
Medlab's shares were suspended by the ASX in late February after the company encountered financial difficulties following its unsuccessful attempt to list on NASDAQ.
Medlab had been counting on a US listing to unlock new capital for the business.
Consultancy Hall Chadwick was brought in to manage a restructuring process, and an update issued in June indicated that discussions were ongoing with parties interested in acquiring Medlab's assets, which include pain relief drug NanaBis and the NanoCelle drug delivery technology.
Whether any agreements have been finalised remains unknown.
